Edwards Lifesciences Corporation (EW)
NYSE
85.78
-0.70 (-0.81%)
Closed
Oct 7, 2026
Day's Range
85.4987.30
52 wk Range
72.3096.29
Financial Statements - EW - Edwards Lifesciences Corporation
Revenue
6.06B▲ 11.5%
Net Income
1.06B▼ 74.4%Net Margin 17.6%
EBITDA
1.96B▲ 11.4%
Free Cash Flow
1.33B▲ 413.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.06B | 5.43B | 6B | 5.38B | 5.23B | 4.38B |
| Cost of Goods | 1.33B | 1.11B | 1.37B | 1.08B | 1.24B | 1.08B |
| Gross Profit | 4.73B | 4.32B | 4.62B | 4.30B | 3.98B | 3.30B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 1.63B | 1.48B | 1.72B | 1.78B | 1.58B | 1.31B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -511.70M | -32.50M | -180.10M | -38.10M | 116.20M | -407.50M |
| Pre Tax Income | 1.27B | 1.54B | 1.59B | 1.76B | 1.70B | 916.70M |
| Income Tax | 216.90M | 152.10M | 198.70M | 245.50M | 198.90M | 93.30M |
| Net Income | 1.06B | 4.16B | 1.39B | 1.52B | 1.50B | 823.40M |
| EPS Basic | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 | 1.32 |
| EPS Diluted | 1.83 | 6.97 | 2.3 | 2.44 | 2.38 | 1.3 |
| Basic Shares Outstanding | 584.80M | 597.70M | 606.70M | 619M | 623.30M | 622.60M |
| Diluted Shares Outstanding | 584.80M | 597.70M | 606.70M | 619M | 623.30M | 622.60M |
| Ebit | 1.29B | 1.56B | 1.61B | 1.78B | 1.72B | 932.50M |
| Ebitda | 1.96B | 1.76B | 1.94B | 1.96B | 1.74B | 1.44B |
| Net Income Continuous Operations | 1.06B | 4.16B | 1.39B | 1.52B | 1.50B | 823.40M |
| Minority Interests | 4.10M | 4.90M | 3M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
